Search hospitals > Colorado > Denver
Colorado Blood Cancer Institute
Claim this profileDenver, Colorado 80218
Global Leader in Cancer
Global Leader in Multiple Myeloma
Conducts research for Plasma Cell Neoplasms
Conducts research for Leukemia
Conducts research for Lymphoma
294 reported clinical trials
12 medical researchers
Summary
Colorado Blood Cancer Institute is a medical facility located in Denver, Colorado. This center is recognized for care of Cancer, Multiple Myeloma, Plasma Cell Neoplasms, Leukemia, Lymphoma and other specialties. Colorado Blood Cancer Institute is involved with conducting 294 clinical trials across 446 conditions. There are 12 research doctors associated with this hospital, such as Nicholas DiBella, Alireza Eghtedar, Michael Tees, MD, and Marcello Rotta.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Multiple Myeloma
Global LeaderStage II
Stage I
Stage III
Top PIs
Nicholas DiBellaRocky Mountain Cancer Centers-Boulder5 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
103 reported clinical trials
193 drugs studied
Alireza EghtedarColorado Blood Cancer Institute2 years of reported clinical research
Studies Acute Myeloid Leukemia
Studies Leukemia
11 reported clinical trials
24 drugs studied
Michael Tees, MDColorado Blood Cancer Institute4 years of reported clinical research
Studies Lymphoma
Studies Non-Hodgkin's Lymphoma
7 reported clinical trials
10 drugs studied
Marcello RottaColorado Blood Cancer Institute1 year of reported clinical research
Studies Acute Myeloid Leukemia
Studies Myeloid Leukemia
6 reported clinical trials
12 drugs studied
Clinical Trials running at Colorado Blood Cancer Institute
Breast Cancer
Multiple Myeloma
Acute Myeloid Leukemia
Lymphoma
Leukemia
Lung Cancer
Plasma Cell Neoplasms
Non-Small Cell Lung Cancer
Cancer
Melanoma
Questionnaire Choice
for Cancer Data Quality
The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.
Recruiting1 award N/A11 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Mobile Health
for Breast Cancer
This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to enhanced usual care (EUC), where patients only use the WiseBag, to monitor medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor. To ensure CDK4/6 inhibitors achieve their full clinical benefit, patients need to take them as prescribed, following a complex treatment schedule. Forgetfulness was the most common reason reported for medication non adherence. Using the WiseBag along with CONCURxP or enhanced usual care may improve medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor.
Recruiting1 award N/A10 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Colorado Blood Cancer Institute?
Colorado Blood Cancer Institute is a medical facility located in Denver, Colorado. This center is recognized for care of Cancer, Multiple Myeloma, Plasma Cell Neoplasms, Leukemia, Lymphoma and other specialties. Colorado Blood Cancer Institute is involved with conducting 294 clinical trials across 446 conditions. There are 12 research doctors associated with this hospital, such as Nicholas DiBella, Alireza Eghtedar, Michael Tees, MD, and Marcello Rotta.